Pancreatic Cancer Research

ResearcherNagoya City UniversityActive in the last 2 years

Hiromichi Murase

Matched on OpenAlex author ID A5071307602. Sources: OpenAlex.

Their work

Papers
9
Trials
0
Grants
0
Labs led
0
Collaborators
14
Papers, trials and grants by year

2022: 2 papers · 2023: 2 papers · 2024: 2 papers · 2025: 1 paper · 2026: 2 papers

Papers 9

  1. Interleukin-1 receptor type 1 in pancreatic cancer progression and metastasis: a review. Co-author DOI 10.1007/s10147-026-03000-7↗
  2. Kaempferol Inhibits MMP-1-Mediated Migration and Invasion in Gemcitabine-Resistant Pancreatic Cancer Cells. Co-author DOI 10.3390/nu18030380↗
  3. The Natural Compound CalebinA Suppresses Gemcitabine Resistance and Tumor Progression by Inhibiting Angiogenesis and Invasion Through NF-κB Signaling in Pancre… Co-author DOI 10.3390/nu17162641↗
  4. Expression of ZKSCAN3 protein suppresses proliferation, migration, and invasion of pancreatic cancer through autophagy. Co-author DOI 10.1111/cas.16173↗
  5. The Natural Product Parthenolide Inhibits Both Angiogenesis and Invasiveness and Improves Gemcitabine Resistance by Suppressing Nuclear Factor κB Activation in… Co-author DOI 10.3390/nu16050705↗
  6. Upregulation of integrin‑linked kinase enhances tumor progression in gemcitabine‑resistant pancreatic cancer. Co-author DOI 10.3892/or.2023.8601↗
  7. Girdin regulates both migration and angiogenesis in pancreatic cancer cell lines. Co-author DOI 10.3892/or.2023.8606↗
  8. 10Z‑Hymenialdisine inhibits angiogenesis by suppressing NF‑κB activation in pancreatic cancer cell lines. Co-author DOI 10.3892/or.2022.8259↗
  9. Enhanced CXCL12/CXCR4 signaling increases tumor progression in radiation‑resistant pancreatic cancer. Co-author DOI 10.3892/or.2022.8279↗

Closest collaborators

The 14 strongest of 14 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yoichi Matsuo · 9 shared papers, 2022–2026 · strength 1.65
  2. Shuji Takiguchi · 9 shared papers, 2022–2026 · strength 1.65
  3. Tomokatsu Kato · 8 shared papers, 2022–2026 · strength 1.41
  4. Kenta Saito · 8 shared papers, 2022–2026 · strength 1.41
  5. Keisuke Nonoyama · 7 shared papers, 2023–2026 · strength 1.38
  6. Yuki Denda · 7 shared papers, 2023–2026 · strength 1.38
  7. Hiroki Takahashi · 7 shared papers, 2022–2025 · strength 1.13
  8. Hiroyuki Imafuji · 6 shared papers, 2022–2024 · strength 0.93
  9. Mamoru Morimoto · 6 shared papers, 2022–2024 · strength 0.93
  10. Saburo Sugita · 4 shared papers, 2024–2026 · strength 0.80
  11. Yuki Eguchi · 4 shared papers, 2024–2026 · strength 0.80
  12. Yuichi Hayashi · 4 shared papers, 2022–2023 · strength 0.57
  13. Kan Omi · 3 shared papers, 2022–2023 · strength 0.41
  14. Goro Ueda · 3 shared papers, 2022–2023 · strength 0.41

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.